Cuba is the largest island of the Caribbean and presents-in many aspects-a challenge for visitors from all over the world. Internet access is very limited, credit cards otherwise accepted worldwide are useless, and the currency market is almost nonexistent. These limitations-and others-not only reduce the economic development of the country but also represent a challenge for Cubans. This is probably the reason why Cubans are known the world over for their inventiveness.
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Health care in Cuba is guided by some fundamental basic principles such as the state and social character of medicine, access, and universality as well as the implementation of the latest scientific and technologic advances consistent with the realities of a low-income country. The Cuban National Health System is highly structured, prevention-oriented, and gives special attention to continuing medical education.
Useful and impressively cost-effective solutions have been implemented for decades in Cuba in response to epidemics, noncommunicable diseases, and other health-related problems and are now offered to other countries as humanitarian support. By focusing on primary care and health promotion, the Cuban health care model strives to identify and produce solutions to health problems at the community level.
This highly structured, prevention-oriented system has produced impressive, positive results. Vaccination rates in Cuba are among the highest in the world. 2 The life expectancy of 77 and 81
years from birth in males and females, respectively (virtually identical to that in the United States), and the infant mortality rate in Cuba has fallen from more than 80 per 1000 live births in the 1950s to o 5 per 1000 live births today.
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A number of different innovations represent Cuban developments in medical science. One of the most representative, in my opinion, is Heberprot-P. 5 Because diabetes mellitus has become a significant health problem throughout the world, the Center for Genetic Engineering and Biotechnology in Havana, Cuba, has designed an integrated strategy for the preclinical testing, pharmaceutical development, production, clinical trials, and business negotiations for an intralesion-injectable drug used for treating diabetic foot ulcers. This product, Heberprot-P, which uses epidermal growth factor as its active ingredient, avoids amputations, is the only registered drug of its type, and has already had considerable medical, social, and economic influence in Cuba and in other nations, placing national science and the Cuban health system at the forefront of the fight against this disorder.
In this issue, we present some important scientific research studies carried out in Cuba. The letter to the editor and the first original research article, concerning Heberprot-P, came from the large experience of the authors with using this novel product. Another article illustrates an ongoing study evaluating hepatitis C vaccines, whereas a separate article presents novel data about the clinical profile and treatment of autoimmune liver diseases in Cuban patients. No less important, the latest advances in immunotherapy and some important approaches related to digestive disturbances are reviewed.
The growing concern among those who recognize that health care resources are finite has promoted policies of cost reduction and an in-depth analysis of what is fair and equitable in the provision of health services. For scientists in Cuba, even considering the economic limitation and their own necessities, efforts to guarantee a healthy population are considered primary.
